[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351983-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351983-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","bioprinted-bladder-cancer-organoids-model-system-for-prediction-of-chemotherapy-response-and-drug-screening","Bioprinted Bladder Cancer Organoids Model System for Prediction of Chemotherapy Response and Drug Screening","","Bladder cancer is a highly heterogeneous disease with widely varying presentation, prognosis, and treatment response, contributing to substantial mortality. Resistance to chemotherapy and contraindications in patients with comorbidities highlight the need for improved drug-screening platforms. This study bioprinted GelMA-based organoids containing bladder cancer cell lines across different grades to model muscle-invasive disease. Grade-dependent tumor proliferation and progression were observed, and standard chemotherapies produced responses consistent with in vivo patient data. The organoids also enabled testing of the PI3K/CDK4/6/CDK9 inhibitor LCI139, supporting their value for rapid, reproducible drug evaluation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/bioprinted-bladder-cancer-organoids-model-system-for-prediction-of-chemotherapy-response-and-drug-screening/351983/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/bioprinted-bladder-cancer-organoids-model-system-for-prediction-of-chemotherapy-response-and-drug-screening/351983.png","ImageObject",300,407,{"name":42,"@type":43},"Fans","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are better drug-screening platforms needed for bladder cancer?","Question",{"text":63,"@type":64},"Bladder cancer shows extensive genetic and molecular heterogeneity, which often drives chemotherapy resistance and variable response. Treatment can also be contraindicated in patients with certain comorbidities, increasing the need for improved screening tools.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What model system did the study create?",{"text":68,"@type":64},"The authors bioprinted GelMA-based organoids containing bladder cancer cell lines across different grades to model muscle-invasive bladder cancer.",{"name":70,"@type":61,"acceptedAnswer":71},"How did the organoids support chemotherapy and drug testing?",{"text":72,"@type":64},"Standard-of-care chemotherapies produced grade-dependent tumor responses that matched in vivo patient data. The model was also used to test LCI139, demonstrating potential for evaluating newly developed drugs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351983,1790182504,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nBioprinted Bladder Cancer Organoids Model System for Prediction of Chemotherapy Response and Drug Screening  \nRandall G. Bissette 1,2, Zachary Congress 1, Gemma Nomdedeu-Sancho 1, Nadeem Wajih 1, Krishnaiah Maddeboina 3 and Shay Soker 1, *  \nAcademic Editor: Abby Parrill  \nReceived: 2 June 2026  \nRevised: 30 June 2026  \nAccepted: 1 July 2026  \nPublished: 7 July 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA  \n2 Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA  \n3 Atrium Health Levine Cancer Center, Charlotte, NC 28204, USA  \n* Correspondence: [shay.soker@wfusm.edu](shay.soker@wfusm.edu)  \nAbstract  \nBladder cancer is the fifth most common cancer in the United States, causing approximately 17,000 deaths annually. Due to its vast genetic and molecular heterogeneity, presentation, prognosis, and therapeutic response vary greatly between individuals. To improve patient outcomes, there is a need for better drug-screening platforms. The genetic heterogeneity of bladder cancer often leads to chemotherapy resistance or low response rates. Moreover, chemotherapies are often contraindicated in patients with select comorbidities. Organoids offer a better option to replicate the tumor microenvironment than traditional 2D cell cultures, improving drug development and personalized therapy. In this study, we bioprinted gelatin-methacrylol (GelMA)-based organoids containing bladder cancer cell lines of different grades to model muscle-invasive bladder cancer. In the organoids, we observed distinct grade-dependent tumor proliferation and progression dynamics. Treatment with standard-of-care chemotherapies revealed a grade-dependent tumor response consistent with in vivo patient data, highlighting the suitability of these organoids for rapid, reliable drug testing. Lastly, we used the organoids to test LCI139, a novel small-molecule inhibitor of PI3K, CDK4/6, and CDK9 designed for the treatment of epithelial cancers, underscoring the potential of our model to evaluate the efficacy of newly developed drugs. The ability to quickly biofabricate reproducible bladder cancer organoids that are adaptable to different tumor grades represents a novel strategy to create an in vitro platform with strong potential to predict treatment outcomes of bladder cancer patients.  \nKeywords: organoids; bladder cancer; small molecule inhibitor; drug testing; CDK inhibitor  \n1. Introduction  \nIn 2025, there were an estimated 84,870 new bladder cancer cases, representing 4.2% of all new cancer diagnoses. Bladder cancer was responsible for 17,420 deaths, and 2.8% of cancer-related mortality [1] . On presentation, 70–75% have non-muscle-invasive disease, and 5% have metastasis. However, over a 5-year period, 40–80% of non-muscle-invasive cases progress to muscle-invasive bladder cancer (MIBC) [2] . The 5-year survival rate of MIBC is estimated to be 60–70%, with this number cratering to 5% when distant metastasis is present [3] .  \nTreatment of bladder cancer depends on risk stratification, which considers clinical staging and pathological grading, with more aggressive approaches reserved for patients at  \nhigher risk. Staging is defined by tumor invasion depth, and grading is based upon the morphological appearance of tumor cells on pathology. Muscle invasion is considered a crucial factor in determining appropriate treatment and rapidly elevates the severity of intervention. For low-or intermediate-risk bladder cancer, intravesical chemotherapy—commonly gemcitabine—should be performed at the time of transurethral resection of the bladder tumor (TURBT) [4] . For non-metastatic muscle-invasive bladder cancer, neoadjuvant cisplatin ","cbCaikQnDwulZ21G","https://ap.wps.com/l/cbCaikQnDwulZ21G","pdf",8997695,14,"English","# Abstract\n# Keywords\n# 1. Introduction\n## Epidemiology and survival context\n## Risk-stratified treatment overview\n## Molecular heterogeneity and resistance rationale\n## Need for improved drug-screening tools","[{\"question\":\"Why are better drug-screening platforms needed for bladder cancer?\",\"answer\":\"Bladder cancer shows extensive genetic and molecular heterogeneity, which often drives chemotherapy resistance and variable response. Treatment can also be contraindicated in patients with certain comorbidities, increasing the need for improved screening tools.\"},{\"question\":\"What model system did the study create?\",\"answer\":\"The authors bioprinted GelMA-based organoids containing bladder cancer cell lines across different grades to model muscle-invasive bladder cancer.\"},{\"question\":\"How did the organoids support chemotherapy and drug testing?\",\"answer\":\"Standard-of-care chemotherapies produced grade-dependent tumor responses that matched in vivo patient data. The model was also used to test LCI139, demonstrating potential for evaluating newly developed drugs.\"}]","Bioprinted Bladder Cancer Organoids Model System for Prediction of Chemotherapy Response and Drug Screening | PDF",1790096677,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b57c961267d1e602958b397e411598a5.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7140bfabccb326e227230c69446cbb7.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bf32eb1324c4cd36207fe216927ed2c.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5969c97cc1a4ebf589c7652c5ec94eb3.webp",980,1385]